Antibiotics Market Forecasts to 2030 – Global Analysis By Product Type (Beta Lactam & Beta Lactamase Inhibitors, Quinolone, Macrolide, Aminoglycosides, Fluoroquinolones, Sulfonamides and Other Product Types), Drug Origin, Spectrum Of Activity, Mechanism O

Antibiotics Market Forecasts to 2030 – Global Analysis By Product Type (Beta Lactam & Beta Lactamase Inhibitors, Quinolone, Macrolide, Aminoglycosides, Fluoroquinolones, Sulfonamides and Other Product Types), Drug Origin, Spectrum Of Activity, Mechanism Of Action, Route Of Administration, Application, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Antibiotics Market is accounted for $42.5 billion in 2023 and is expected to reach $57.9 billion by 2030 growing at a CAGR of 4.5% during the forecast period. A group of potent medications known as antibiotics are used to treat bacterial infections. They function by either eradicating germs or preventing their development and procreation. Since they can be used to treat bacterial illnesses and save lives, antibiotics are crucial components of contemporary medicine. Single-celled germs called bacteria are the specific target of antibiotics. They are ineffective against viruses, such as those that spread the flu or the common cold. Antiviral drugs are typically used to treat viral infections. Antibiotics can fight germs in a number of different ways, some antibiotics cause the bacterial cell wall to be damaged, which leads to the germs bursting or hinder the production of necessary proteins by bacteria by interfering with protein synthesis. Some antibiotics specifically target bacterial DNA, preventing it from being replicated or repaired. Use of antibiotics responsibly and stewardship are essential.

According to the Center for Disease Dynamics, Economics & Policy (CDDEP), the defined daily doses of antibiotics consumed in the U.S., decreased by 19.8% from 3,630 million in 2010 to 2,913 million in 2020.
Market Dynamics

Driver

Thorough research and development to create cutting-edge combination therapies

Bacteria can become resistant to drugs when they create defences against their effects. Antibiotic misuse and overuse has expedited the development of antibiotic-resistant bacteria, posing a serious threat to world health. Infections with resistance may be more challenging to treat and may result in higher morbidity and fatality rates. Because current antibiotics are becoming less effective against bacteria that have developed drug resistance, the creation of new antibiotics is crucial. Without new antibiotics, basic medical procedures like surgeries, organ transplants, and cancer treatments become riskier due to the possibility of bacterial infections, even if some bacterial infections are already difficult to treat. Hence all the above factors are propelling the growth of the market.

Restraint

Increasing antibiotic resistance

One of the biggest problems with antibiotics is they can lose their effectiveness over time if bacteria develop resistance to them. Antibiotic overuse and misuse can hasten the emergence of bacterial strains that are resistant to them. This may result in infections that are more difficult to treat and may call for stronger antibiotics with higher potential for toxicity. Moreover, depending on the medicine, an antibiotic may have a variety of side effects. Nausea, vomiting, diarrhea, dermatitis, and allergic responses are typical adverse effects. Antibiotics occasionally have more serious adverse effects, such as liver or kidney damage which hamper the growth of the market.

Opportunity

Approaches in precision medicine

According to the particular bacterial strain causing the infection, antibiotic treatment can be customized with precision medicine. The probability of treatment failure can be decreased by identifying the best antibiotic for a specific infection with the aid of genomic analysis and diagnostic technologies. However, to spur innovation and handle market issues, there has to be a rise in public, corporate, and charitable funding in antibiotic research and development. The development of novel antibiotics can be accelerated by international alliances and collaborations between pharmaceutical corporations, academic institutions, and governing bodies create more and more opportunities for the market growth.

Threat

Superinfections with few therapeutic alternatives

Superinfections can occur as a result of antibiotics upsetting the body's bacterial balance. Antibiotic use, for instance, can cause Clostridium difficile (C. difficile) infections, which can be serious and difficult to cure. The number of viable antibiotics is decreasing as antibiotic resistance spreads. Patients may have few options when dealing with certain drug-resistant bacterial diseases because there are occasionally few or no treatments available.

Covid-19 Impact

The market for antibiotics was affected by the COVID-19 epidemic. The need for antibiotics to treat COVID-19 greatly rose during the pandemic's early stages. For instance, Pfizer reported encouraging results from a coronavirus (COVID-19) clinical trial conducted in France utilizing azithromycin (Zithromax) and hydroxychloroquine in March 2020. Following these clinical trials, azithromycin gained popularity as a COVID-19 treatment. As a result of the pandemic's strong demand for antibiotics, the market expanded significantly. After the pandemic, it is anticipated to see stable growth.

The beta lactam & beta lactamase inhibitors segment is expected to be the largest during the forecast period

The beta lactam & beta lactamase inhibitors segment is estimated to have a lucrative growth, as beta-lactam antibiotic called cephalosporins prevents the production of peptidoglycan in bacterial cell walls. It treats a variety of gram-positive and gram-negative bacterial illnesses. These antibiotics are frequently used to treat upper respiratory tract infections, meningitis, skin infections, and pneumonia. With time, numerous improvements were developed to increase the effectiveness of cephalosporins against different microorganisms. A generation referred to every improvement. Cephalosporins are prescribed and used widely throughout the world due to their broad application and adaptable route of administration, which is the main driving factor for the segment.

The online pharmacy segment is expected to have the highest CAGR during the forecast period

The online pharmacy segment is anticipated to witness the highest CAGR growth during the forecast period, due to the rising use of advanced technology by middle-income countries, it is anticipated that there will be a dramatic increase in the delivery and purchase of medicines online throughout the forecasted time period. The preference for internet pharmacies over brick-and-mortar pharmacies is mostly a result of the pandemic situation. As a result, it is predicted that it will accelerate the segment's growth throughout the projection period. Hospitals typically prefer to treat large patient groups. Another important aspect that is likely to affect the growth of the hospital pharmacies segment throughout the forecast period is the rise in the number of specialty hospitals.

Region with largest share

North America is projected to hold the largest market share during the forecast period as north America has led the worldwide market because to the superior healthcare facilities that the government has made available to its citizens. Due to their busy lifestyles and rapid development, developed nations have large populations that are afflicted with illnesses and other chronic diseases. This turns out to be a key component fuelling the market for antibiotics during the anticipated timeframe of expansion.

Region with highest CAGR

Europe is projected to have the highest CAGR over the forecast period, owing to be the second-most prominent area. The primary factors influencing the demand for these medications in the European market and are the quick growth of the healthcare infrastructure in a number of European nations, the rising investment in research and development activities, and the expanding number of hospitals in the region. However the entry of cutting-edge medications into the market due to the presence of major industry participants in these nations has significantly increased demand.

Key players in the market

Some of the key players profiled in the Antibiotics Market include Abbott Laboratories, AbbVie, Inc., Allergan Plc., Astellas Pharma, Bayer Healthcare AG, Daiichi Sankyo, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson Inc., Lupin Pharmaceuticals, Inc., Melinta Therapeutics LLC, Merck & Co. Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. And Cipla, Inc.

Key Developments

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. The transaction expands Abbott's presence in diabetes care, building on its world-leading FreeStyle Libre® portfolio of continuous glucose monitoring technology

In August 2023, Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the companies’ supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide)

In April 2023, Abbott announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease.

Product Types Covered
• Beta Lactam & Beta Lactamase Inhibitors
• Quinolone
• Macrolide
• Aminoglycosides
• Fluoroquinolones
• Sulfonamides
• Other Product Types

Drug Origins Covered
• Synthetic
• Semisynthetic
• Natural

Spectrum Of Activities Covered
• Broad-Spectrum Antibiotic
• Narrow-Spectrum Antibiotic

Mechanism Of Actions Covered
• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Protein Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Other Mechanism Of Actions

Route Of Administrations Covered
• Oral
• Parenteral
• Topical
• Other Route Of Administrations

Applications Covered
• Ear Infection
• Gastrointestinal Infections
• Respiratory Infections
• Septicemia
• Skin Infections
• Urinary Tract Infections
• Other Applications

Distribution Channels Covered
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels

End Users Covered
• Specialty Clinic
• Hospital
• Homecare
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements